{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:04:56Z","timestamp":1791644696495,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster","id":[{"id":"https:\/\/ror.org\/01856cw59","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 was approved after the VISION trial demonstrated significant benefit in metastatic castration-resistant prostate cancer (mCRPC). This study evaluated outcomes of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 with or without concurrent Androgen Receptor Pathway Inhibitors (ARPI) in a real-world setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed electronic health records of mCRPC patients treated with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 in routine clinical practice between June 2023 and August 2024. Primary endpoints were overall survival (OS) and PSA50 response; secondary endpoints included PSA-progression-free survival (PSA-PFS), radiographic PFS (rPFS), and percentage PSA change from baseline. Baseline characteristics were compared using Mann\u2013Whitney U and chi-square tests. Survival outcomes were evaluated using Kaplan\u2013Meier and Cox regression analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 108 patients, 65 received [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 monotherapy and 43 concurrent ARPI therapy. Baseline characteristics were generally well balanced, with slightly higher hemoglobin and a trend toward lower PSA in the ARPI group. No significant between-group differences were observed for median OS (12.7 vs. 13.5 months;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.96), PSA50 response rate (51.2% vs. 52.3%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.91), PSA-PFS (6.3 vs. 6.2 months;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.54), or median PSA change from baseline (\u221239.0% vs. \u221243.1%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.24). A non-significant trend in rPFS favored the ARPI group (10.6 vs. 9.8 months;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.057). On multivariable Cox regression, concurrent ARPI use was not independently associated with OS (adjusted HR 1.29;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.33).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this real-world cohort of ARPI- and taxane-pretreated mCRPC patients, concurrent ARPI use during [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 was not independently associated with improved clinical outcomes. These exploratory findings do not provide evidence to support routine continuation of ARPI beyond progression at the time of radioligand therapy initiation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08060-5","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:22:34Z","timestamp":1783668154000},"page":"7028-7037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and outcomes of [177Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8903-1913","authenticated-orcid":false,"given":"Martin","family":"Rust","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Backhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Platte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Matheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Stegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"8060_CR1","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.ccr-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2023;29:1651\u20137. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-2875.","journal-title":"Clin Cancer Res"},{"key":"8060_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/nejmoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/nejmoa2107322.","journal-title":"N Engl J Med"},{"key":"8060_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","volume":"36","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, et al. Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36:1319\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.003.","journal-title":"Ann Oncol"},{"key":"8060_CR4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/s0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"8060_CR5","unstructured":"U.S. Food and Drug Administration. FDA expands Pluvicto's metastatic castration-resistant prostate cancer indication. 28.03.2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Accessed 1 Mar 2026"},{"key":"8060_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147431","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H, et al. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22147431.","journal-title":"Int J Mol Sci"},{"key":"8060_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","volume":"5","author":"B Meller","year":"2015","unstructured":"Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66. https:\/\/doi.org\/10.1186\/s13550-015-0145-8.","journal-title":"EJNMMI Res"},{"key":"8060_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071696","author":"F Rosar","year":"2022","unstructured":"Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA, et al. Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14071696.","journal-title":"Cancers (Basel)"},{"key":"8060_CR9","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. J Nucl Med. 2019;60:950\u20134. https:\/\/doi.org\/10.2967\/jnumed.118.223099.","journal-title":"J Nucl Med"},{"issue":"Supplement 2","key":"8060_CR10","doi-asserted-by":"publisher","first-page":"S1627","DOI":"10.1016\/j.annonc.2025.09.101","volume":"36","author":"ST Tagawa","year":"2025","unstructured":"Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, et al. LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Ann Oncol. 2025;36(Supplement 2):S1627\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.101.","journal-title":"Ann Oncol"},{"key":"8060_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:563\u201371. https:\/\/doi.org\/10.1016\/s1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"key":"8060_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, et al. Overall survival and quality of life with 177LuLu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26:291\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(25)00009-9.","journal-title":"Lancet Oncol"},{"key":"8060_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.01.015","author":"K Fizazi","year":"2026","unstructured":"Fizazi K, Attard G, Azad AA, Baciarello G, Beltran H, Bjartell A, et al. Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.01.015.","journal-title":"Ann Oncol"},{"key":"8060_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41391-024-00906-z","volume":"28","author":"HD McManus","year":"2025","unstructured":"McManus HD, Dorff T, Morgans AK, Sartor O, Shore N, Armstrong AJ. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 2025;28:672\u201383. https:\/\/doi.org\/10.1038\/s41391-024-00906-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"8060_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209:1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"J Urol"},{"key":"8060_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"8060_CR17","doi-asserted-by":"publisher","unstructured":"Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G et al. Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4. JCO. 2026:JCO2502834. https:\/\/doi.org\/10.1200\/JCO-25-02834","DOI":"10.1200\/JCO-25-02834"},{"key":"8060_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1200\/jco.2025.43.5_suppl.121","volume":"43","author":"O Yazdanpanah","year":"2025","unstructured":"Yazdanpanah O, Calais J, Chi KN, de Bono JS, Deymann S, El-Haddad G, et al. Efficacy of 177 Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. J Clin Oncol. 2025;43:121. https:\/\/doi.org\/10.1200\/jco.2025.43.5_suppl.121.","journal-title":"J Clin Oncol"},{"key":"8060_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.euo.2025.06.004","volume":"8","author":"M Muniz","year":"2025","unstructured":"Muniz M, Sartor O, Orme JJ, Koch RM, Scharf Z, Heath EI, et al. Outcomes for 177LuLu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025;8:1087\u201393. https:\/\/doi.org\/10.1016\/j.euo.2025.06.004.","journal-title":"Eur Urol Oncol"},{"key":"8060_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07682-5","author":"F Rosar","year":"2025","unstructured":"Rosar F, Khreish F, Burgard C, Fursov A, Blickle A, Bartholom\u00e4 M, et al. Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07682-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8060_CR21","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, H\u00fcttmann T, Seitz AK, K\u00fcbler H, Serfling SE, Schl\u00f6telburg W, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50:3465\u201374. https:\/\/doi.org\/10.1007\/s00259-023-06281-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8060_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22:26\u201345. https:\/\/doi.org\/10.1038\/s41585-024-00900-z.","journal-title":"Nat Rev Urol"},{"key":"8060_CR23","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.ccr-19-1485","volume":"26","author":"K Current","year":"2020","unstructured":"Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, et al. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity. Clin Cancer Res. 2020;26:2946\u201355. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-1485.","journal-title":"Clin Cancer Res"},{"key":"8060_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018;1:78\u201382. https:\/\/doi.org\/10.1016\/j.euo.2018.03.010.","journal-title":"Eur Urol Oncol"},{"key":"8060_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13550-023-01048-4","volume":"13","author":"I Sonni","year":"2023","unstructured":"Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, et al. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023;13:95. https:\/\/doi.org\/10.1186\/s13550-023-01048-4.","journal-title":"EJNMMI Res"},{"key":"8060_CR26","unstructured":"ClinicalTrials.gov. An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA-positive First-line mCRPC (PSMAndARPI). 17.02.2026. https:\/\/clinicaltrials.gov\/study\/NCT06894511. Accessed 1 Mar 2026."},{"key":"8060_CR27","unstructured":"ClinicalTrials.gov. A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare). 2026. https:\/\/clinicaltrials.gov\/study\/NCT05849298. Accessed 1 Mar 2026."},{"key":"8060_CR28","unstructured":"ClinicalTrials.gov. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (AcTFirst). 24.02.2026. https:\/\/clinicaltrials.gov\/study\/NCT06855277. Accessed 1 Mar 2026."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08060-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:31:44Z","timestamp":1790929904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08060-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8060"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08060-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DV received a research grant of the Clinician Scientist program CareerS of the University of M\u00fcnster and of CRC 1450 \u2013 431460824 funded by the Deutsche Forschungsgemeinschaft (DFG) \u2013 outside of this work. KR reports lectureship or consulting honoraria from AAA\/Novartis, ABX, ABX CRO, Amgen, Bayer Healthcare, UroTrials, and Pharmtrace. KR received research funding from German Research Foundation (DFG): Project Nr: 564651276, RA 3222\/5-1. MB reports lectureship or consulting honoraria from AAA\/Novartis, Johnson & Johnson, MSD, BMS, AstraZeneca, Amgen, Bayer Healthcare, Medudy, Sanofi, Orion, Astellas, Pfizer, Ipsen, Eisai, Gilead, Recordati, and Pharmtrace. WR reports consulting honoraria from ITM.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Medical Association Westphalia-Lippe (approval no. 2026-153-f-S) and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of this study, individual informed consent was waived by the Ethics Committee.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual personal data or identifying information is included in this manuscript; therefore, separate consent to publish was not required.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}